Gilead Sciences to Present at Upcoming Investor Conferences
With an FDA approval in hand for primary biliary cholangitis (PBC) treatment Livdelzi (seladelpar), Gilead Sciences enters arenas that are both new and old.
Merck & Co. is paying $700 million upfront to challenge Amgen in a blood cancer market. The deal will give Merck global rights to Curon Biopharmaceutical’s CD3xCD19 bispecific, positioning the Big Pharma as a rival to Amgen and AstraZeneca in oncology and Cullinan Therapeutics in autoimmune disease.
With Gilead Sciences' stated focus to grow in oncology, the company's recent quarterly updates have placed a heavy emphasis on its developments in the cancer space. But, with a unique pre-exposure prophylaxis (PrEP) offering for HIV that could “redefine” the market, the drugmaker is touting lofty ambitions there, too.
Gilead quarterly profit beats Street estimates, revenue up 5%
Gilead is spending $320 million to buy out Johnson & Johnson’s global royalties for primary biliary cholangitis drug seladelpar a week before the FDA is
As a nation where 90% of all people living with HIV know their diagnosis and are being treated, Germany has made great strides to advance its HIV care goals. Yet the country acknowledges it still has significant work to do to close the gaps in diagnosis that still exist, mainly in its rural and migrant communities.
Gilead Sciences Announces Second Quarter 2024 Financial Results
This week on “The Top Line,” we discuss two studies in HIV research that were presented at the 25th International AIDS Conference in Germany.
On June 14, Merck & Co. posted a new entry on ClinicalTrials.gov. The study, coded TroFuse-020, marked the 10th global phase 3 trial the New Jersey pharma has logged for its Kelun Biotech-partnered antibody-drug conjugate, sacituzumab tirumotecan, in about eight months.